Literature DB >> 21440682

Relationship between HLA-DRB1 polymorphism and susceptibility or resistance to multiple sclerosis in Caucasians: a meta-analysis of non-family-based studies.

Qiong Zhang1, Chun-Ying Lin, Qiang Dong, Jian Wang, Wei Wang.   

Abstract

OBJECTIVE: To identify the contribution of HLA-DRB1 alleles to susceptibility or resistance to multiple sclerosis (MS) in Caucasians through a meta-analysis of non-family-based studies.
METHODS: A systematic review of case-control studies in Caucasians was performed. Studies examining allele or phenotype frequencies were analyzed separately. Odds ratio (OR) and 95% confidence intervals (CIs) were used. We also used the relatively predispositional effect (RPE) method to analyze several allele frequency studies to avoid skewed results due to some strongly associated alleles.
RESULTS: A total of 5464 cases and 7809 controls from 14 allele frequency studies and a total of 5401 cases and 7538 controls from 23 phenotype frequency studies were analyzed. DRB1*15 was definitely the strongest risk factor for MS (allele group, Pc<0.00013, OR 2.59, 95%CI 2.34-2.87; phenotype group, Pc<0.00013, OR 3.35, 95%CI 2.95-3.80). DRB1*03 frequencies were significantly increased among MS cases in the phenotype group (Pc= 0.0013, OR 1.21, 95%CI 1.09-1.33) but not in the allele group. DRB1*14 and DRB1*07 showed protective effects against MS in both groups (DRB1*14, allele group, Pc<0.00013, OR 0.53, 95%CI 0.42-0.66; phenotype group, Pc<0.00013, OR 0.57, 95%CI 0.45-0.71; DRB1*07, allele group, Pc<0.0026, OR 0.75, 95%CI 0.64-0.87; phenotype group, Pc<0.00013, OR 0.67, 95%CI 0.61-0.73). By RPE method, DRB1*14, and DRB1*07 showed protective effects after excluding DRB1*15 from the analysis. DRB1*03 was significantly higher in MS cases than controls after removing both DRB1*15 and DRB1*14.
CONCLUSIONS: In Caucasians, we highlighted the definite protective role of HLA-DRB1*14 and DRB1*07 for MS. DRB1*03 is probably the only risk factor for MS besides DRB1*15 and a common genetic foundation for autoimmune disease. Targeting to these alleles may have potential values in prevention or therapy for MS in the specific population.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21440682     DOI: 10.1016/j.autrev.2011.03.003

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  12 in total

Review 1.  Autoimmunity in 2011.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2012-08       Impact factor: 8.667

2.  Which clinical risk factors determine a pathological urodynamic evaluation in patients with multiple sclerosis? an analysis of 100 prospective cases.

Authors:  A Wiedemann; M Kaeder; W Greulich; H Lax; J Priebel; R Kirschner-Hermanns; I Füsgen
Journal:  World J Urol       Date:  2012-01-07       Impact factor: 4.226

3.  A systematic review and meta-analysis of HLA class II associations in patients with IgG4 autoimmunity.

Authors:  Anja Panhuber; Giovanni Lamorte; Veronica Bruno; Hakan Cetin; Wolfgang Bauer; Romana Höftberger; Astrid C Erber; Florian Frommlet; Inga Koneczny
Journal:  Sci Rep       Date:  2022-06-02       Impact factor: 4.996

Review 4.  Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner.

Authors:  Celia Oreja-Guevara; Heinz Wiendl; Bernd C Kieseier; Laura Airas
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

5.  Association between Human Leukocyte Antigen Type and Keratinocyte Carcinoma Risk in Renal Transplant Recipients.

Authors:  Yuhree Kim; David Wojciechowski; Vikram Pattanayak; Hang Lee; Maryam M Asgari
Journal:  J Invest Dermatol       Date:  2019-10-24       Impact factor: 8.551

Review 6.  Prevalence of multiple sclerosis in Latin America and its relationship with European migration.

Authors:  Edgar Correa; Víctor Paredes; Braulio Martínez
Journal:  Mult Scler J Exp Transl Clin       Date:  2016-09-02

7.  Association between HLA-DRB1 polymorphisms and pemphigus vulgaris: a meta-analysis.

Authors:  L Yan; J-M Wang; K Zeng
Journal:  Br J Dermatol       Date:  2012-08-20       Impact factor: 9.302

8.  Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles.

Authors:  Inger-Lise Mero; Marte W Gustavsen; Hanne S Sæther; Siri T Flåm; Pål Berg-Hansen; Helle B Søndergaard; Poul Erik H Jensen; Tone Berge; Anja Bjølgerud; Aslaug Muggerud; Jan H Aarseth; Kjell-Morten Myhr; Elisabeth G Celius; Finn Sellebjerg; Jan Hillert; Lars Alfredsson; Tomas Olsson; Annette Bang Oturai; Ingrid Kockum; Benedicte A Lie; Bettina Kulle Andreassen; Hanne F Harbo
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

9.  HLA-DRB1*14 is a protective allele for multiple sclerosis in an admixed Colombian population.

Authors:  Jaime Toro; David Cuellar-Giraldo; Camilo Díaz-Cruz; Lisseth-Estefania Burbano; Claudia-Marcela Guío; Saúl Reyes; Fabián Cortes; Simón Cárdenas-Robledo; Diana M Narváez; Wilmer Cárdenas; Alexandra Porras; María-Claudia Lattig; Helena Groot de Restrepo
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-12-24

10.  HLA-DQB1 and HLA-DRB1 Variants Confer Susceptibility to Latent Autoimmune Diabetes in Adults: Relative Predispositional Effects among Allele Groups.

Authors:  Minting Zhang; Shuhuang Lin; Xiaoling Yuan; Ziqi Lin; Zunnan Huang
Journal:  Genes (Basel)       Date:  2019-09-13       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.